- Home
- CLRB vs EVAX Comparison
CLRB vs EVAX Comparison
Compare CLRB & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- EVAX
- Stock Information
- Founded
- CLRB 2002
- EVAX 2008
- Country
- CLRB United States
- EVAX Denmark
- Employees
- CLRB N/A
- EVAX N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLRB Health Care
- EVAX Health Care
- Exchange
- CLRB Nasdaq
- EVAX Nasdaq
- Market Cap
- CLRB 10.7M
- EVAX 8.7M
- IPO Year
- CLRB N/A
- EVAX 2021
- Fundamental
- Price
- CLRB $0.25
- EVAX $0.90
- Analyst Decision
- CLRB Buy
- EVAX Strong Buy
- Analyst Count
- CLRB 2
- EVAX 2
- Target Price
- CLRB $28.00
- EVAX $11.00
- AVG Volume (30 Days)
- CLRB 3.8M
- EVAX 75.1K
- Earning Date
- CLRB 11-18-2024
- EVAX 10-31-2024
- Dividend Yield
- CLRB N/A
- EVAX N/A
- EPS Growth
- CLRB N/A
- EVAX N/A
- EPS
- CLRB N/A
- EVAX N/A
- Revenue
- CLRB N/A
- EVAX $3,295,000.00
- Revenue This Year
- CLRB N/A
- EVAX $4,845.21
- Revenue Next Year
- CLRB N/A
- EVAX $30.30
- P/E Ratio
- CLRB N/A
- EVAX N/A
- Revenue Growth
- CLRB N/A
- EVAX N/A
- 52 Week Low
- CLRB $0.23
- EVAX $0.91
- 52 Week High
- CLRB $4.45
- EVAX $13.61
- Technical
- Relative Strength Index (RSI)
- CLRB 6.45
- EVAX 20.63
- Support Level
- CLRB $0.23
- EVAX $0.91
- Resistance Level
- CLRB $0.28
- EVAX $1.20
- Average True Range (ATR)
- CLRB 0.07
- EVAX 0.17
- MACD
- CLRB -0.10
- EVAX -0.01
- Stochastic Oscillator
- CLRB 2.70
- EVAX 4.85
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.